WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018056736) NOVEL NATURAL KILLER CELL LINE AND USE THEREOF
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/056736    International Application No.:    PCT/KR2017/010438
Publication Date: 29.03.2018 International Filing Date: 22.09.2017
IPC:
C12N 5/0783 (2010.01), C12N 15/85 (2006.01), A61K 35/17
Applicants: SLBIGEN INC. [KR/KR]; 700, Daewangpangyo-ro, Bundang-gu Seongnam-si Gyeonggi-do 13488 (KR)
Inventors: SUNG, Young Chul; (KR).
KIM, Sae Won; (KR).
KANG, Moon Cheol; (KR)
Agent: HAN, Yun Ho; (KR)
Priority Data:
10-2016-0122097 23.09.2016 KR
Title (EN) NOVEL NATURAL KILLER CELL LINE AND USE THEREOF
(FR) NOUVELLE LIGNÉE DE CELLULES TUEUSES NATURELLES ET UTILISATION CORRESPONDANTE
(KO) 신규 자연살해 세포주 및 그의 용도
Abstract: front page image
(EN)The present invention relates to a novel natural killer cell line and use thereof and, more particularly, to a novel natural killer cell line which is positive to CD2, CD11a, CD25, CD45, CD54, CD56, and HLA-DR; and negative to CD1a, CD3, CD4, CD8, CD14, CD16, CD20, CD23, CD34, TCRαβ, and TCRγδ, and use thereof such as a pharmaceutical composition comprising the same for treatment of cancer.
(FR)La présente invention concerne une nouvelle lignée de cellules tueuses naturelles et une utilisation correspondante et, plus particulièrement, une nouvelle lignée de cellules tueuses naturelles qui est positive à CD2, CD11a, CD25, CD45, CD54, CD56 et HLA-DR ; et négative à CD1a, CD3, CD4, CD8, CD14, CD16, CD20, CD23, CD34, TCRαβ et TCRγδ et l'utilisation correspondante comme composition pharmaceutique la comprenant pour le traitement du cancer.
(KO)본 발명은 신규 자연살해 세포주 및 그의 용도에 관한 것으로서, 보다 구체적으로는 CD2, CD11a, CD25, CD45, CD54, CD56 및 HLA-DR은 양성; 및 CD1a, CD3, CD4, CD8, CD14, CD16, CD20, CD23, CD34, TCRαβ 및 TCRγδ는 음성인 신규 자연살해 세포주 및 이를 포함하는 암 치료용 약학적 조성물 등 그의 용도를 제공한다.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: Korean (KO)
Filing Language: Korean (KO)